Welcome to our dedicated page for PharmChem news (Ticker: PCHM), a resource for investors and traders seeking the latest updates and insights on PharmChem stock.
PharmChem, Inc. (OTC: PCHM) delivers innovative drug testing solutions through its proprietary PharmChek® Sweat Patch technology. This news hub provides investors and industry professionals with essential updates on strategic developments, regulatory milestones, and advancements in non-invasive pharmaceutical diagnostics.
Access timely press releases covering earnings reports, manufacturing innovations, and compliance updates. Our curated collection includes details on product enhancements, forensic testing applications, and corporate strategy decisions relevant to the drug detection market.
Discover updates on PharmChem's specialized manufacturing processes, quality control initiatives, and responses to evolving industry standards. This resource serves as your central reference for understanding the company's position within competitive diagnostic technology markets.
Bookmark this page for real-time updates on PCHM's operational developments and strategic direction. Check regularly for authoritative information supporting informed analysis of this niche pharmaceutical diagnostics provider.
PharmChem (OTC: PCHM), a leading provider of sweat patches for drug abuse detection, announced on February 3, 2025, that its Board of Directors has initiated an exploration of strategic alternatives. The company will consider various options including acquisitions, potential sale, merger, or a debt-financed special dividend.
The Board believes PharmChem would be more valuable as part of a larger company and better positioned to serve customers. The company has established a data room for interested parties but has not retained a financial advisor, citing the Board's sufficient experience to guide the process.
The company emphasized there is no guarantee this review will result in any transaction or strategic outcome, and no specific timeline has been set. Further announcements will only be made if the Board approves a specific transaction or if disclosure is legally required.
PharmChem, Inc. (OTC: PCHM) has announced a modified Dutch auction tender offer to repurchase up to $5 million of its common stock at prices between $3.25 and $3.75 per share. Shareholders can tender shares within this price range before the offer expires on May 31, 2022. The board believes this method provides an efficient opportunity for shareholders to sell their shares. However, the offer is subject to certain conditions and does not require a minimum number of shares to be tendered.
PharmChem has responded to a proxy battle initiated by Cedar Creek Partners, urging shareholders to vote for the white proxy card and disregard the opposition's blue card. The company asserts that its current management and board are essential for continued success, citing substantial growth in sales from $769,000 to $6.7 million and an increase in pre-tax income from a loss of $128,000 to $2.1 million since 2005. The opposition's inexperience and intentions to replace key executives could jeopardize the company's progress and relationships within the industry.
